|
gptkbp:instanceOf
|
pharmaceutical drug
|
|
gptkbp:activeDuring
|
metformin
|
|
gptkbp:chemicalFormula
|
C4H11N5O
|
|
gptkbp:clinicalTrials
|
gptkb:Asia
gptkb:Australia
gptkb:Canada
gptkb:USA
Europe
Phase 3
NCT01234567
|
|
gptkbp:contraindication
|
renal impairment
lactic_acidosis
|
|
gptkbp:date
|
FDA_approved
|
|
gptkbp:developedBy
|
gptkb:OPKO_Health,_Inc.
|
|
gptkbp:dosageForm
|
tablet
|
|
gptkbp:formulation
|
oral tablet
|
|
gptkbp:future_plans
|
Phase 3
|
|
gptkbp:historical_analysis
|
NCT01234567
NCT01234568
NCT01234569
NCT01234570
NCT01234571
NCT01234572
NCT01234573
NCT01234574
NCT01234575
NCT01234576
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
OPKO 1100
|
|
gptkbp:interactsWith
|
alcohol
other antidiabetic medications
|
|
gptkbp:mandates
|
Type 2 diabetes mellitus
|
|
gptkbp:manufacturer
|
gptkb:OPKO_Health,_Inc.
|
|
gptkbp:market
|
2015
|
|
gptkbp:marketedAs
|
brand name
|
|
gptkbp:offersCoursesIn
|
gptkb:Australia
gptkb:Brazil
gptkb:Canada
gptkb:France
gptkb:Germany
gptkb:India
gptkb:Japan
gptkb:Mexico
gptkb:UK
gptkb:USA
|
|
gptkbp:patentStatus
|
patented
|
|
gptkbp:regulatoryCompliance
|
gptkb:FDA
EMA
|
|
gptkbp:route
|
oral
|
|
gptkbp:sideEffect
|
nausea
abdominal pain
diarrhea
|
|
gptkbp:skills
|
500 mg
|
|
gptkbp:triggerType
|
increases insulin sensitivity
decreases_hepatic_glucose_production
|
|
gptkbp:usedFor
|
treatment of diabetes
|